Greg Verdine, LifeMine
January 7, 2021 11:01 AM ESTUpdated January 8, 01:47 AM
Financing
Startups

Rick Klaus­ner fronts cash for his fun­gus out­fit LifeM­ine and brings on No­bel lau­re­ate to fur­ther push can­cer dis­cov­ery

Max Gelman

Senior Editor

More than three years af­ter launch­ing with a $55 mil­lion Se­ries A, fun­gus play­er LifeM­ine Ther­a­peu­tics is back with a tri­fec­ta of new good­ies …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times